Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals (NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric...

詳細記述

保存先:
書誌詳細
出版年:J Am Soc Nephrol
主要な著者: Dahan, Karine, Debiec, Hanna, Plaisier, Emmanuelle, Cachanado, Marine, Rousseau, Alexandra, Wakselman, Laura, Michel, Pierre-Antoine, Mihout, Fabrice, Dussol, Bertrand, Matignon, Marie, Mousson, Christiane, Simon, Tabassome, Ronco, Pierre
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Nephrology 2017
主題:
Clinical Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5198292/
https://ncbi.nlm.nih.gov/pubmed/27352623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016040449
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料